HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Measuring Consumer Exposure Confounds US FDA’s Evaluation Of Cannabinoid Safety In Supplements

Executive Summary

Acting commissioner Woodcock reminds manufacturers and marketers that a consumer’s exposure to cannabidiol and other cannabinoids likely comes from using multiple products daily. “How do you control exposure of people in a nonprescription setting?”

You may also be interested in...



Congressional Report Highlights Lack of Mandatory Supplement Listing As DSHEA 2.0 Talks Continue

The Congressional Research Service published a dietary supplements report on 20 September that provides an overview of the industry and current regulatory issues, including ‘limitations’ in the US FDA’s authority over supplements and, in particular, the absence of mandatory product listing.

Church & Dwight Includes Cannabinoids Among Nair Bladeless Shave Luxury Treatment Choices

C&D launching three-product Nair Bladeless Shave line extension, including one with cannabinoids. First Response line Comfort Check extension contains three early tests and five pregnancy strips.

Room Available In US Pharma Industry For OTC Switch Leader: Has Perrigo Made A Reservation?

Acquiring HRA Pharma, Perrigo could take OTC switch lead, likely starting with HRA’s daily oral contraceptive before moving to numerous other potential candidates. Pharmas previously busy in switch have other priorities for their consumer health businesses.

Related Content

Topics

UsernamePublicRestriction

Register

RS151748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel